UK accepts J&J's money-back guarantee

It's official: the UK's National Health Service will start using Johnson & Johnson's Velcade, under an unprecedented money-back-guarantee program. Patients who respond to the drug will be fully funded. Patients who respond only minimally or not all all will be taken off Velcade, and J&J will refund the cost to NHS. The guarantee was the only way J&J could persuade the National Institute for Clinical Excellence--the drug gatekeepers for NHS--to reimburse for the drug at all.

- check out the CNN Money report
- read an analysis of the deal in The Telegraph

Related Articles:
J&J drug gets money-back guarantee. Report
Positive Velcade data fuels stock rise. Report
NHS fights expensive Alzheimer's drugs. Report
Metric: Biotech drugs fueling costs. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.